Navigation Links
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
Date:10/27/2008

agues showed that ceftaroline has the greatest overall in vitro bactericidal activity against community-associated MRSA (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin non-susceptible S. aureus (DNSSA) compared to vancomycin, daptomycin, clindamycin, linezolid, TMP/SMX, and ceftriaxone.(6)

--Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline (CPT) (Poster C1-185)(7)

Dr. R. Hinshaw and colleagues evaluated the risk of ceftaroline resistance development using an in vitro model. There was no propensity for resistance development to ceftaroline when serially tested against important skin and community-acquired pneumonia pathogens, including methicillin-susceptible S. aureus (MSSA), MRSA, community-acquired MRSA (CA-MRSA), vancomycin-intermediate S. aureus (VISA), penicillin-susceptible S. pneumoniae (PSSP), penicillin-resistant S. pneumoniae (PRSP), and beta-lactamase-negative H. influenzae.(7)

About Complicated Skin and Skin Structure Infections (cSSSIs)

cSSSIs are caused by gram-positive bacteria, such as MRSA, and common gram-negative bacteria.(8) cSSSIs are among the most common infections treated in the hospital setting,(9) and MRSA infections, now the most frequent cause of cSSSI presenting to emergency departments in the United States (U.S.) and the cause of more than 18,000 deaths in 2005, are becoming more common in patients in both the hospital and community settings.(10)

According to the Centers for Disease Control and Prevention, about 70% of bacterial infections are resistant to at least one drug.(11) Many are resistant to multiple drugs making cSSSIs, especially due to MRSA, challenging to treat.(12) cSSSIs can become extremely serious, leading to hospitalization with increased risk for morbidity and mortality and increased healthcare costs.(11) In a study of patients in the emergency room with skin and skin-structure
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
2. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
3. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
4. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Kuvan Receives Positive Opinion From CHMP for European Approval
9. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
10. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
11. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Fla. , Sept. 2, 2014  Technology Applications ... announced that its wholly-owned subsidiary Renuell Int,l, Inc. has ... Aeronautics and Space Administration ("NASA") at the Johnson Space ... See photos: tapplic.com/houstonphotos/ ... "We are very pleased to announce our latest, exclusive ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... pioneered a new highly efficient, cost effective approach ... U.S. Patent No. 8,820,265 by the U.S. Patent ... proprietary to Opertech. , “Opertech’s taste ... is the first automated high throughput system for ...
(Date:9/2/2014)... Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... announced the appointment of Debra Zack , ... appointment of Lloyd Rowland , senior vice ... "Debra,s expertise in biologics clinical development ...
(Date:9/2/2014)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... targeting specific pathogens that cause serious infections and ... preclinical toxicology study of SYN-004. Per U.S. Food ... was required to move the Company,s lead anti-infective, ... effects of Clostridium difficile (C. difficile), ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... ArunA Biomedical, Inc., the first,company to commercialize human ... that William T. Sharp has been named President,and ... leadership,responsibilities, Mr. Sharp has also been appointed to ... Steven Stice, PhD, who will,remain ArunA,s Chairman and ...
... July 29 Xceed,Molecular, a pioneer in the ... its new Inflammation Xpress,Chip, a pre-configured array for ... at the 2008 AACC/ASCLS Clinical Lab Expo,(booth 2155). ... E. Washington,Convention Center in Washington, DC., "With ...
... are everywhere from the air we breathe and the food ... are innocuous or even beneficial, and only a handful pose any ... unwanted intruder? , Research from the University of Wisconsin-Madison suggests ... , A study appearing online this week in the Proceedings ...
Cached Biology Technology:ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155 2Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155 3Symbiotic microbes induce profound genetic changes in their hosts 2
(Date:9/2/2014)... integrity? Tell the truth; everyone has a tipping point. We ... lie if the benefit is great enough. Now, scientists have ... that decision. , The result was published online this ... prefer to be honest, even if lying is beneficial," said ... at the Virginia Tech Carilion Research Institute , where ...
(Date:9/2/2014)... in Taiyuan, China, have substantially improved the health of ... reduction in costs associated with loss of life and ... the Columbia Center for Children,s Environmental Health (CCCEH) at ... University, the Center of Diseases Control and Prevention of ... Health. , The study is the first to document ...
(Date:9/2/2014)... When you accidentally touch a hot oven, you rapidly ... neural circuits involved in sensing and responding to such ... players. , Duke researchers have made a surprising discovery ... pain in worms, and have built a structural model ... Nature Communications , may help direct new strategies ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Clean air halves health costs in Chinese city 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... Local and regional researchers collect large amounts of ... but the researchers that create the economic and climate ... Now, thanks to a $2 million grant from the ... the modelers through the Penn State Institutes of Energy ...
... in Spanish . Wheat growers in ... to climate change in the decades ahead, thanks to U.S. ... with the USDA,s Agricultural Research Service (ARS) installed infrared heaters ... Center in Maricopa, Ariz., to simulate growing conditions expected by ...
... the recent prediction that half of all Americans will have ... a new genetic discovery published online in the FASEB ... to why: we took an evolutionary "wrong turn." In the ... loss of function in a gene called "CMAH" may make ...
Cached Biology News:DOE grant joins climate modeling with local, regional empirical data 2Examining climate change effects on wheat 2New research suggests that obesity and diabetes are a downside of human evolution 2